| Project/Area Number |
15K10973
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岡田 英志 岐阜大学, 医学部附属病院, 講師 (30402176)
竹村 元三 朝日大学, 歯学部, 教授 (40283311)
鈴木 浩大 岐阜大学, 医学部附属病院, 助教 (80724583)
|
|---|
| Research Collaborator |
SUGAHARA Kazuki
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 敗血症 / 血管内皮傷害 / ホーミングペプチド / 腎障害 / 血管内皮障害 |
|---|
| Outline of Final Research Achievements |
A tissue-penetrating homing peptide, CARSKNKDC (CAR) has previously demonstrated the unique ability to facilitate transport of co-administered drugs into injured endothelial cell. Co-administration of hydrocortisone and CAR could improve the endothelial disorder and survival in sepsis using lower amounts of hydrocortisone.Mice were given lipopolysaccharide (LPS, 20 mg/kg). Subsequently, five different treatments were initiated: saline only; CAR peptide-alone administration 500 ug; hydrocortisone 0.2mg/kg or 10mg/kg ; and CAR co-administered with hydrocortisone 0.2mg/kg. Hydrocortisone and /or CAR peptide were injected intraperitoneally at 3, 12 and 24 hours after LPS administration. Forty-eight hours after LPS administration, combined thrapy group showed the best survival ratio. These results suggest that co-administration of hydrocortisone and CAR peptide is a highly effective treatment strategy for endothelial disorder in sepsis.
|
